Vinorelbine and low-dose cyclophosphamide as maintenance therapy in the treatment of Ewing sarcoma rationale for the international INTER-EWING-1 trial for Ewing sarcoma patients.

Cancer Treat RevJul 27, 2026 (epub)
Clinical ResearchOncology (Medical)

Lianne M Haveman, Lisa L Hjalgrim, Cristina Mata Fernández et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the feasibility of maintenance therapy for Ewing sarcoma (ES) using vinorelbine and low-dose cyclophosphamide. The review included 20 studies on ES and other pediatric sarcomas, highlighting modest clinical activity in heavily pretreated patients. The strongest evidence came from rhabdomyosarcoma, where maintenance therapy improved long-term survival.

Key findings

  • 20 studies were included, with 11 focusing on Ewing sarcoma patients.
  • Vinorelbine and low-dose cyclophosphamide showed modest clinical activity in relapsed or refractory Ewing sarcoma.
  • The EpSSG RMS 2005-trial demonstrated improved long-term survival with vinorelbine/cyclophosphamide maintenance in rhabdomyosarcoma.

Why it matters

Understanding the potential role of maintenance therapy in Ewing sarcoma could help improve outcomes in a patient population with high relapse rates. This review provides a rationale for further investigation into effective maintenance strategies.

Source

PubMed · PMID 42561548

Published in Cancer Treat Rev. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.